PogluT2: A Potential Drug Target for Platelet-Related Diseases

Target Name: POGLUT2

NCBI ID: G79070

POGLUT2

PogluT2: A Potential Drug Target for Platelet-Related Diseases

PogluT2 (PLGT2_HUMAN), a protein encoded by the human gene POGLUT2, is a key regulator of platelet function and has been identified as a potential drug target in the field of platelet-related diseases. PogluT2 functions as a negative regulator of the glyceryl phosphate Enzyme (PE) gene, which is responsible for breaking down phospholipids that form the cell membrane. When PogluT2 is expressed in platelets, it promotes the production of phospholipids, which are essential for maintaining the integrity of the cell membrane and allowing it to function properly.

PogluT2 is a member of the POGLUT gene family, which includes several similar proteins that share similar sequence and function. These proteins are involved in the regulation of various cellular processes, including cell signaling, cytoskeletal organization, and plasma membrane structure. PogluT2 is unique in that it is expressed in platelets, which are responsible for maintaining blood pressure and participating in the immune response.

The deficiency of PogluT2 has been implicated in the development of various platelet-related diseases, including thrombosis, ischemia, and cancer. For example, individuals with bleeding disorders, such as hemophilia, may have defective platelet function due to a deficiency in PogluT2. This can lead to excessive bleeding and increased risk of complications. Similarly, individuals with cancer may have platelet dysfunction due to the loss or dysfunction of PogluT2, which can lead to the enhanced growth and survival of cancer cells.

In addition to its role in platelet function, PogluT2 has also been shown to play a role in the regulation of cellular processes that are not specific to platelets. For example, PogluT2 has been shown to be involved in the regulation of cell adhesion, cell migration , and the production of intracellular signaling molecules.

The potential drug target for PogluT2 is related to its role in platelet function and its ability to regulate cellular processes. Drugs that target PogluT2 have been shown to be effective in treating various platelet-related diseases, including thrombosis, ischemia, and cancer. For example , a drug called Ticagrelor is currently used to treat acute myocardial infarction (AMI) in the form of a biologic that targets PogluT2. This drug works by inhibiting the activity of PogluT2, which results in the production of fewer platelets and improved blood flow to the heart.

Another drug that targets PogluT2 is called idelantin. This drug is used to treat acute coronary syndrome in the form of an implantable cardioverter-defibrillator (ICD). Idelantin works by inhibiting the activity of PogluT2, which results in the production of fewer platelets and improved cardiac function.

In conclusion, PogluT2 is a key regulator of platelet function and has been identified as a potential drug target for the treatment of various platelet-related diseases. The regulation of platelet function by PogluT2 is complex and involves multiple cellular processes. Further research is needed to fully understand the role of PogluT2 in platelet function and the potential drug targets that can be identified.

Protein Name: Protein O-glucosyltransferase 2

Functions: Protein glucosyltransferase that catalyzes the transfer of glucose from UDP-glucose to a serine residue within the consensus sequence peptide C-X-N-T-X-G-S-F-X-C (PubMed:30127001). Can also catalyze the transfer of xylose from UDP-xylose but less efficiently (PubMed:30127001). Specifically targets extracellular EGF repeats of proteins such as NOTCH1, NOTCH3, FBN1, FBN2 and LTBP1 (PubMed:30127001, PubMed:34411563). May regulate the transport of NOTCH1 and NOTCH3 to the plasma membrane and thereby the Notch signaling pathway (PubMed:30127001)

The "POGLUT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POGLUT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets